Campbell & CO Investment Adviser LLC Has $205,000 Stock Position in PTC Therapeutics, Inc. $PTCT

Campbell & CO Investment Adviser LLC lowered its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) by 77.5% during the third quarter, HoldingsChannel reports. The fund owned 3,347 shares of the biopharmaceutical company’s stock after selling 11,546 shares during the quarter. Campbell & CO Investment Adviser LLC’s holdings in PTC Therapeutics were worth $205,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of PTCT. PNC Financial Services Group Inc. grew its position in PTC Therapeutics by 42.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 995 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 295 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of PTC Therapeutics by 247.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,143 shares of the biopharmaceutical company’s stock valued at $56,000 after buying an additional 814 shares during the period. Exchange Traded Concepts LLC acquired a new stake in PTC Therapeutics during the third quarter worth about $92,000. Globeflex Capital L P acquired a new stake in PTC Therapeutics during the second quarter worth about $91,000. Finally, Plato Investment Management Ltd bought a new position in PTC Therapeutics during the second quarter valued at about $92,000.

PTC Therapeutics Stock Performance

PTCT opened at $75.25 on Friday. The firm has a market cap of $6.04 billion, a price-to-earnings ratio of 8.79 and a beta of 0.49. The firm’s 50-day simple moving average is $77.17 and its 200-day simple moving average is $64.65. PTC Therapeutics, Inc. has a twelve month low of $35.95 and a twelve month high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.19) by $1.39. The firm had revenue of $211.01 million during the quarter, compared to the consensus estimate of $177.42 million. PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. The firm’s quarterly revenue was up 7.2% on a year-over-year basis. During the same period last year, the firm posted ($1.39) EPS. As a group, sell-side analysts anticipate that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.

Insider Buying and Selling

In other PTC Therapeutics news, insider Neil Gregory Almstead sold 71,928 shares of PTC Therapeutics stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $83.44, for a total value of $6,001,672.32. Following the completion of the transaction, the insider owned 100,625 shares in the company, valued at approximately $8,396,150. The trade was a 41.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Glenn Md Phd Steele, Jr. sold 12,000 shares of the business’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $76.35, for a total value of $916,200.00. Following the completion of the transaction, the director directly owned 18,500 shares in the company, valued at approximately $1,412,475. This represents a 39.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 306,682 shares of company stock valued at $24,139,117 in the last ninety days. 5.50% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Wall Street Zen upgraded PTC Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Wells Fargo & Company upped their target price on PTC Therapeutics from $73.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. Citigroup raised their target price on PTC Therapeutics from $50.00 to $75.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 5th. Weiss Ratings reissued a “hold (c)” rating on shares of PTC Therapeutics in a report on Monday, December 29th. Finally, TD Cowen restated a “hold” rating on shares of PTC Therapeutics in a research note on Wednesday, November 5th. Nine equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, PTC Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $77.27.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.